U.S. Markets closed

Allergan plc (AGN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
202.66-7.34 (-3.50%)
At close: 4:01PM EDT

202.20 -0.46 (-0.23%)
After hours: 7:51PM EDT

People also watch
BIIBCELGVRXGILDREGN
Full screen
Previous Close210.00
Open208.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range202.60 - 208.50
52 Week Range184.50 - 256.80
Volume5,878,871
Avg. Volume2,103,382
Market Cap67.75B
Beta1.24
PE Ratio (TTM)6.17
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (1.30%)
Ex-Dividend Date2017-08-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Does Allergan plc (AGN) Affect Your Portfolio Returns?
    Simply Wall St.12 hours ago

    How Does Allergan plc (AGN) Affect Your Portfolio Returns?

    If you are a shareholder in Allergan plc’s (NYSE:AGN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • How is the Age-Related Macular Degeneration Space Faring Now?
    Zacks13 hours ago

    How is the Age-Related Macular Degeneration Space Faring Now?

    The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

  • Barrons.comyesterday

    Allergan: Just How Far Will Big Pharma Go To Protect Its Patents?

    Specialty drug maker Allergan (AGN) raised more than a few eyebrows this month when news broke of the deal it made with the Saint Regis Mohawk Tribe of upstate New York to protect patents for one of its blockbuster drugs. In fact, one of Wall Street biggest drug analysts cited the deal as one of three reasons it has downgraded Allergan’s stock and slashed its price target. Allergan decided earlier this month to transfer ownership of the patents protecting the dry eye treatment Restasis, Allergan’s second biggest selling drug, to the tribe to prevent the scrutiny of the U.S. Patent & Trademark Office.